In A549, H460 NSCLC cells, and metastatic cells derived from a lung cancer patient, CBD (3 μM) elevated the susceptibility of these lung cancer cells to lymphokine-activated killer (LAK) cell-mediated tumor-cell killing in an ICAM-1-dependent manner [30]. Here, ICAM1 is linked to neoplasm.